FAIRFAX FINANCIAL HOLDINGS LTD/ CAN: CVS HEALTH CORP (CVS): Quarterly 13F Position History
As of Q1 2026, FAIRFAX FINANCIAL HOLDINGS LTD/ CAN reported 2,712,000 shares of CVS HEALTH CORP (CVS), worth $194.8M and representing 10.0% of its 13F equity book. The position first appeared in Q4 2019 and has been disclosed across 26 13F-HR filings in Pactolio's tracked window.
- 2,712,000Shares Held (Latest Filing)
- $194.8MReported Market Value (Latest Filing)
- 10.0%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$20.4MQuarter-over-Quarter Value Change
- 2,712,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 26 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,712,000 | 0 | — | $194.8M | 10.0% | $71.8 |
| Q4 2025 | 2,712,000 | 0 | — | $215.2M | 10.3% | $79.3 |
| Q3 2025 | 2,712,000 | 0 | — | $204.4M | 9.9% | $75.4 |
| Q2 2025 | 2,712,000 | 0 | — | $187.0M | 10.0% | $68.9 |
| Q1 2025 | 2,712,000 | 0 | — | $183.8M | 10.0% | $67.8 |
| Q4 2024 | 2,712,000 | +2,712,000 | — | $121.7M | 7.8% | $44.9 |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 15,000 | -100.0% | $0 | 0.0% | — |
| Q1 2024 | 15,000 | 0 | — | $1.2M | 0.1% | $79.7 |
| Q4 2023 | 15,000 | 0 | — | $1.2M | 0.1% | $78.9 |
| Q3 2023 | 15,000 | 0 | — | $1.0M | 0.1% | $69.8 |
| Q2 2023 | 15,000 | 0 | — | $1.0M | 0.1% | $69.1 |
| Q1 2023 | 15,000 | 0 | — | $1.1M | 0.1% | $74.3 |
| Q4 2022 | 15,000 | 0 | — | $1.4M | 0.0% | $93.2 |
| Q3 2022 | 15,000 | 0 | — | $1.4M | 0.0% | $95.4 |
| Q2 2022 | 15,000 | 11,500 | -43.4% | $1.4M | 0.0% | $92.7 |
| Q1 2022 | 26,500 | 0 | — | $2.7M | 0.1% | $101.2 |
| Q4 2021 | 26,500 | 0 | — | $2.7M | 0.1% | $103.1 |
| Q3 2021 | 26,500 | 0 | — | $2.2M | 0.1% | $84.8 |
| Q2 2021 | 26,500 | 0 | — | $2.2M | 0.1% | $83.4 |
| Q1 2021 | 26,500 | 0 | — | $2.0M | 0.1% | $75.2 |
| Q4 2020 | 26,500 | 0 | — | $1.8M | 0.1% | $68.3 |
| Q3 2020 | 26,500 | 0 | — | $1.5M | 0.1% | $58.4 |
| Q2 2020 | 26,500 | 0 | — | $1.7M | 0.1% | $64.9 |
| Q1 2020 | 26,500 | 0 | — | $1.6M | 0.1% | $59.4 |
| Q4 2019 | 26,500 | — | — | $2.0M | 0.1% | $74.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did FAIRFAX FINANCIAL HOLDINGS LTD/ CAN first disclose a CVS position in 13F-HR filings?
FAIRFAX FINANCIAL HOLDINGS LTD/ CAN first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2019-12-31 (Q4 2019). The position has appeared on 26 reported quarters within Pactolio's tracked window.
What was FAIRFAX FINANCIAL HOLDINGS LTD/ CAN's most recent quarter-over-quarter share-count change in CVS?
FAIRFAX FINANCIAL HOLDINGS LTD/ CAN held the same 2,712,000 shares of CVS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent FAIRFAX FINANCIAL HOLDINGS LTD/ CAN's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.